Atossa Therapeutics, Inc. (ATOS): R&D Expense
$21.18M
Year ended 2025-12-31
$21.20M
Trailing 12 months to 2026-06-30
+12.0%
3-year compound annual growth
+26.2%
5-year compound annual growth
+24.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.18M | +50.1% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $14.12M | -18.6% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $17.33M | +14.9% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $15.08M | +63.8% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $9.21M | +39.4% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $6.61M | -0.6% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $6.65M | +57.8% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $4.21M | +80.8% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $2.33M | +202.2% | 2019-03-28, From 2017-01-01 |
| 2016-12-31 | $770.4K | -67.3% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $2.36M | +112.5% | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $1.11M | +0.5% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $1.11M | -44.0% | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | $1.97M | n/a | 2014-03-27, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $21.18M | +50.1% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $2.81M | -59.7% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $9.12M | -54.4% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $44.92M | +8.3% |
Compare ATOS, AKTX, VRCA, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗